Blood markers and how the body responds to combined chemotherapy and radiation treatment for esophageal cancer."

"Biomarkers in serum and response to neoadjuvant chemoradiotherapy in esophageal carcinom - biomarkers in blood during nCRT for esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58119

Enrollment

125

Registered

2025-11-01

Start date

2012-03-10

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer cancer of the esophagus

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Above 18 years old.Must be undergoing neoadjuvant chemoradiotherapy (CROSS protocol) for esophageal carcinoma.Must be undergoing neoadjuvant chemoradiotherapy (CROSS protocol) for esophageal carcinoma.

Exclusion criteria

Exclusion criteria: Patients receiving treatments outside of the neoadjuvant chemoradiotherapy (CROSS) protocol (dCRT)  

Design outcomes

Primary

Measure	Time frame
Identifying biomarkers that predict treatment response.	—

Countries

Netherlands

Contacts

Public ContactTJ Huizer

Erasmus MC, Universitair Medisch Centrum Rotterdam

t.j.huizer@erasmusmc.nl0107034523

Outcome results